Not yet recruiting
Safety and Efficacy of VX-828/Deutivacaftor Combination Therapy With and Without Tezacaftor in Subjects With Cystic Fibrosis
2025-523400-72-00· Phase 2· Vertex Pharmaceuticals Inc.· Source
Recruiting
Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis
NCT07697456· Phase 2· AbbVie· Source
Not yet recruiting
GMMG-HD11/DSMM XXI/64007957MMY3010
NCT07671287· Phase 3· University of Heidelberg Medical Center· Source
Recruiting
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants
2025-521762-99-00· Phase 3· University Medical Center Hamburg-Eppendorf· Source
Recruiting
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
NCT07371585· Phase 2· SOLTI Breast Cancer Research Group· Source
Recruiting
Evaluation of Novel Thrombolytic TGD001 in Patients With Acute Ischemic Stroke
2025-522455-26-00· Phase 1/2· TargED Biopharmaceuticals B.V.· Source
Recruiting
Efficacy of Top-down Therapy With Mirikizumab Versus Standard of Care With Azathioprine in Patients With Newly Diagnosed Moderate-to-severe Ulcerative Colitis
NCT07235904· Phase 4· University Hospital Schleswig-Holstein· Source
Recruiting
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
NCT07151378· Phase 3· University Hospital Tuebingen· Source
Recruiting
Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype
NCT06486883· Phase 2· MedSIR· Source
Recruiting
A Study to Investigate Efficacy and Safety of Brivekimig in Participants With Crohn's Disease
NCT06958536· Phase 2· Sanofi· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891· Phase 3· Hoffmann-La Roche· Source
Recruiting
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
NCT06652438· Phase 3· Stichting Hemato-Oncologie voor Volwassenen Nederland· Source
Recruiting
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
NCT06790693· Phase 3· Hoffmann-La Roche· Source
Active, not recruiting
A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06588855· Phase 3· Hoffmann-La Roche· Source
Recruiting
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
NCT06081244· Phase 3· Women's Cancer Study Group GmbH· Source
Recruiting
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT06393374· Phase 3· Merck Sharp & Dohme LLC· Source
Active, not recruiting
Individualized Immunotherapy in Early-Stage Unfavorable Classical Hodgkin Lymphoma
NCT04837859· Phase 2· University Of Cologne· Source
Recruiting
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
NCT06357533· Phase 3· AstraZeneca· Source
Recruiting
Randomized Trial in Adult de Novo Ph Positive ALL With Chemotherapy, Imatinib or Ponatinib, Blinatumomab and SCT
NCT06061094· Phase 2· Goethe University· Source
Recruiting
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
NCT05633654· Phase 3· Gilead Sciences· Source
Active, not recruiting
A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products
NCT05476926· Hoffmann-La Roche· Source
Active, not recruiting
A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy
NCT05444257· Phase 3· Vertex Pharmaceuticals Incorporated· Source
Active, not recruiting
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCER PATIENTS
NCT05452213· Phase 4· Institut Für Frauengesundheit GmbH· Source
Recruiting
Combination of Abemaciclib and Endocrine Therapy in Hormone Receptor Positive HER2 Negative Locally Advanced or Metastatic Breast Cancer With Focus on Digital Side Effect Management
NCT05362760· Phase 4· Prof. Wolfgang Janni· Source
Recruiting
Post-resection/Ablation Chemotherapy in Patients With Metastatic Colorectal Cancer (FIRE-9 - PORT / AIO-KRK-0418)
NCT05008809· Phase 3· Dominik Paul Modest· Source
Active, not recruiting
Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)
NCT04602533· Phase 2· Michael Hopp· Source
Active, not recruiting
Sacituzumab Govitecan in Primary HER2-negative Breast Cancer
NCT04595565· Phase 3· GBG Forschungs GmbH· Source
Active, not recruiting
First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
NCT04767594· Pfizer· Source
Active, not recruiting
Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)
NCT02215265· Phase 3· Lisette Nixon· Source